Table 1.
The main features of studies in this meta-analysis.
| Author | Mohsenizadeh | Guler | De Luca | Little | Choudry | |
|---|---|---|---|---|---|---|
| Year | 2022 | 2022 | 2021 | 2020 | 2020 | |
| Country | Iran | Turkey | Italy | United Kingdom | United Kingdom | |
| Study design | Retrospective observational cohort | Retrospective study | Retrospective multicenter registry | Retrospective observational analysis | Single-center, observational study | |
| Sample size | COVID-19+ | 98 | 62 | 62 | 46 | 39 |
| COVID-19- | 1052 | 64 | 310 | 302 | 76 | |
| Age | COVID-19+ | 62.92 ± 12.02 | 60.2 ± 9.5 | 70 (62–76) | 63 (58–67) | 61.7 ± 11.0 |
| COVID-19- | 59.93 ± 11.61 | 63 ± 8 | 70 (62–75) | 63 (55–72) | 61.7 ± 12.6 | |
| Gender (male) | COVID-19+ | 75 (76.5) | 41 (66.1) | 49 (79) | 37 (80.4) | 33 (84.6) |
| COVID-19- | 819 (77.9) | 45 (70.3) | 245 (79) | 241 (79.8) | 57 (75.0) | |
| Hypertension | COVID-19+ | 43 (43.9) | 37 (59.7) | 35 (56.5) | 25 (54) | 28 (71.8) |
| COVID-19- | 506 (48.1) | 37 (57.8) | 176 (56.8) | 153 (50.7) | 32 (42.1) | |
| Diabetes mellitus | COVID-19+ | 54 (55.1) | 30 (48.4) | 10 (16.1) | 15 (32.6) | 18 (46.2) |
| COVID-19- | 483 (45.9) | 35 (54.7) | 67 (21.6) | 71 (23.5) | 20 (26.3) | |
| Hyperlipidemia | COVID-19+ | 44 (44.9) | 27 (43.5) | 25 (40.3) | 24 (52.2) | 24 (61.6) |
| COVID-19- | 612 (58.2) | 22 (34.3) | 125 (40.3) | 100 (33.1) | 28 (36.8) | |
| Smoking | COVID-19+ | 30 (30.6) | 32 (51.6) | 15 (24.2) | 1 (2.2) | 24 (61.6) |
| COVID-19- | 394 (37.5) | 36 (56.3) | 91 (29.4) | 10 (3.3) | 35 (46.1) | |
| Previous MI | COVID-19+ | 13 (13.3) | 6 (9.7) | 8 (12.9) | 5 (10.9) | 6 (15.4) |
| COVID-19- | 92 (8.7) | 18 (28.1) | 29 (9.4) | 38 (12.6) | 3 (3.9) | |
| Door-to-balloon time | COVID-19+ | 56.5 (41–90) | 39 (32–48) | 40 (28–65) | 51 (39–77) | 52 (39–70) |
| COVID-19- | 55 (37–89) | 31 (27–35) | 35 (23–68) | 47 (32–63) | 50 (34.8–57.5) | |
| Total ischemia time | COVID-19+ | 395 (185–655) | 203 (171 –267 | 200 (107–500) | 360 (223–1418) | 240 (120–360) |
| COVID-19- | 375 (195–795) | 185 (137 –242) | 179 (120–291) | 257 (172–580) | 240 (120–420) | |
| Gp2b3a inhibitor use | COVID-19+ | 61 (62.2) | 13 (21) | 21 (33.9) | 26 (56.5) | 23 (59.0) |
| COVID-19- | 483 (45.9) | 6 (9.4) | 71 (22.9) | 117 (38.7) | 7 (9.2) | |
| Thrombus aspiration use | COVID-19+ | 9 (9.2) | 4 (6.2) | 23 (37.1) | 14 (30.4) | 7 (17.9) |
| COVID-19- | 114 (10.8) | 3 (4.7) | 64 (20.6) | 54 (17.9) | 1 (1.3) | |
| TIMI flow 3 at end of case | COVID-19+ | 65 (66.3) | 51 (82.3) | 57 (91.9) | 37 (80.4) | 35 (89.7) |
| COVID-19- | 878 (83.5) | 57 (89.1) | 285 (91.9) | 278 (92.0) | 70 (93.3) | |
| In-hospital mortality | COVID-19+ | 20 (20.4) | 10 (16.1) | 18 (29) | 10 (21.7) | 7 (17.9) |
| COVID-19- | 29 (2.8) | 3 (4.7) | 17 (5.5) | 28 (9.3) | 5 (6.5) | |
COVID-19 = coronavirus disease 2019, GP2b3a = glycoprotein IIb/IIIa, MI = myocardial infarction, TIMI = thrombolysis in myocardial infarction.